Cancer Clinical Research Unit

Inclusion Criteria: - Written informed consent - Females ≥18 years old at the time of signature of the consent form. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 28 days prior to enrollment. - All patients must have histologically proven, locally advanced or metastatic recurrent ovarian and uterine cancer. Patients will be eligible only if available curative therapy does not exist. - Ovarian and uterine cancer should be high-grade and TP53 abnormal by immunohistochemistry or TP53 mutated by genomic profiling. - Patients must be eligible for re-challenge carboplatin and paclitaxel. - Patient must have archival tissue available for molecular profiling. - Measurable disease as per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 at the time of enrollment. - Ability to comply with the protocol and study procedures. - Acceptable study required organ function at screening - Acceptable study required hematologic function at screening - Negative pregnancy test (serum) for women of child-bearing potential (WOCBP) at screening. WOCBP who are sexually active and their partners must agree to use a highly effective form of contraception throughout their participation during the study and for 6 months after the last dose of study treatment. - Resolution of all toxicities of prior therapy or surgical procedures to baseline or Grade 1 (except for neuropathy, hypothyroidism requiring medication, and alopecia, which must have resolved to Grade ≤2). - Any prior radiation must have been completed at least 7 days prior to the start of study treatment, and patients must have recovered from any acute adverse effects prior to the start of study treatment. - Life expectancy ≥12 weeks after the start of the treatment according to the Investigator's judgment. Exclusion Criteria: - Chemotherapy or small molecule antineoplastic agent given within 21 days or